Re-Approval Form

Date: October 11, 2018
Principal Investigator: Sean Bagshaw
Study ID: Pro00060023
Study Title: STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial
Approval Expiry Date: October 10, 2019
Protocol Number: 10/5/2015
Sponsor/Funding Agency: CIHR - Canadian Institutes for Health Research
Sponsor/Funding Agency: Western Sydney University
Canada Research Chair

The Health Research Ethics Board - Biomedical Panel has reviewed the renewal request and file for this project and found it to be acceptable within the limitations of human experimentation.

The re-approval for the study as presented is valid for another year. It may be extended following completion of the annual renewal request. Beginning 30 days prior to expiration, you will receive notices that the study is about to expire. Once the study has expired you will have to resubmit. Any proposed changes to the study must be submitted to the HREB for approval prior to implementation.

All study-related documents should be retained so as to be available to the HREB on request. They should be kept for the duration of the project and for at least five years following study completion. In the case of clinical trials approved under Division 5 of the Food and Drug regulations of Health Canada, study records must be retained for 25 years.

The membership of the Health Research Ethics Board - Biomedical Panel complies with the membership requirements for research ethics boards as defined in Division 5 of the Food and Drug Regulations and the Tri Council Policy Statement. The HREB - Biomedical Panel carries out its functions in a manner consistent with Good Clinical Practices and the Canadian General Standards Board (CAN/CGSB-101.1-2013).

Sincerely,

S.K.M. Kimber, MD, FRCPC
Chair, HREB Biomedical
Note: This correspondence includes an electronic signature (validation and approval via an online system).